# A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

> **NCT05835180** · PHASE1 · COMPLETED · sponsor: **Sagimet Biosciences Inc.** · enrollment: 48 (actual)

## Conditions studied

- Non-alcoholic Steatohepatitis
- Hepatic Impairment
- Cirrhosis

## Interventions

- **DRUG:** TVB-2640 - 50 mg

## Key facts

- **NCT ID:** NCT05835180
- **Lead sponsor:** Sagimet Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-01
- **Primary completion:** 2023-12-18
- **Final completion:** 2023-12-18
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2023-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05835180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05835180, "A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05835180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*